These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38385206)
1. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis. Ercan MB; Kocer B; Altiparmak T; Arslan I Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206 [No Abstract] [Full Text] [Related]
2. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases. N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016 [No Abstract] [Full Text] [Related]
4. Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML. Yokote H; Mori K; Nakamichi K; Matsuda T; Miura Y Neurology; 2024 Oct; 103(7):e209874. PubMed ID: 39213467 [No Abstract] [Full Text] [Related]
5. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104 [TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report. Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841 [TBL] [Abstract][Full Text] [Related]
9. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab. Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501 [No Abstract] [Full Text] [Related]
10. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964 [TBL] [Abstract][Full Text] [Related]
12. Minimal supportive treatment in natalizumab-related PML in a MS patient. Lalive PH; Bridel C; Ferfoglia RI; Kaiser L; Du Pasquier R; Barkhof F; Haller S J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):354-5. PubMed ID: 24957322 [No Abstract] [Full Text] [Related]
13. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab]. Simaniv TO; Ivanova MV; Bryukhov VV; Zakharova MN Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):98-106. PubMed ID: 31156248 [TBL] [Abstract][Full Text] [Related]
14. Deaths and disability from natalizumab are no longer tolerable: Commentary. Hutchinson M Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472 [No Abstract] [Full Text] [Related]